Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy

Br J Cancer. 2000 Jan;82(1):85-7. doi: 10.1054/bjoc.1999.0881.

Abstract

Autoantibodies to the heat shock protein 90 (Hsp 90) have been reported as prognostic marker in breast cancer patients. Sera from 20 high-grade osteosarcoma patients were tested at the time of diagnosis by enzyme-linked immunosorbent assay. Presence of anti-Hsp90 antibodies correlated with a better response to neoadjuvant chemotherapy (P < 0.01), whereas the absence correlated with development of metastases. These data suggest that anti-Hsp90 antibodies might be of predictive value in human osteosarcoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Autoantibodies / blood*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / immunology*
  • Chemotherapy, Adjuvant
  • Child
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Femoral Neoplasms / drug therapy
  • Femoral Neoplasms / immunology
  • HSP90 Heat-Shock Proteins / immunology*
  • Humans
  • Ilium
  • Male
  • Neoplasm Proteins / immunology*
  • Osteosarcoma / drug therapy
  • Osteosarcoma / immunology*
  • Tibia

Substances

  • Autoantibodies
  • HSP90 Heat-Shock Proteins
  • Neoplasm Proteins